Novel psoriasis therapies and patient outcomes, part 1: topical medications.


In recent years, advances in our understanding of inflammatory mediators and the underlying pathogenesis of psoriasis and psoriatic arthritis have shed light on potential therapeutic targets, which has led to the development of several new promising treatments. In this article, key clinical trials, mechanisms of action, patient outcomes, and relevant safety information for these novel topical medications will be evaluated. This article is the first in a 3-part series on treatments presently in the pipeline for the management of psoriasis and psoriatic arthritis including topical agents, biologic treatments, and systemic therapies in phase 2 and phase 3 clinical trials. With novel approaches to the disease process, these therapies may afford more targeted individualized treatment regimens and offer hope to patients with psoriasis and psoriatic arthritis who have reported a suboptimal therapeutic response to conventional therapies.

Citations per Year

Citation Velocity: 16

Averaging 16 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Feely2015NovelPT, title={Novel psoriasis therapies and patient outcomes, part 1: topical medications.}, author={Meghan A Feely and Barry L. Smith and Jeffrey M. Weinberg}, journal={Cutis}, year={2015}, volume={95 3}, pages={164-8, 170} }